These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 28481997)

  • 1. Patterns of Growth, Body Composition, and Lipid Profiles in a South African Cohort of Human Immunodeficiency Virus-Infected and Uninfected Children: A Cross-Sectional Study.
    Ramteke SM; Shiau S; Foca M; Strehlau R; Pinillos F; Patel F; Violari A; Liberty A; Coovadia A; Kuhn L; Arpadi SM;
    J Pediatric Infect Dis Soc; 2018 May; 7(2):143-150. PubMed ID: 28481997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Lopinavir/Ritonavir and Efavirenz-Based Antiretroviral Therapy on the Lipid Profile of Chinese HIV/AIDS Treatment-Naïve Patients in Beijing: A Retrospective Study.
    Dai L; Liu A; Zhang H; Wu H; Zhang T; Su B; Shao Y; Li J; Ye J; Scott SR; Mahajan SD; Schwartz SA; Yu H; Sun L
    Curr HIV Res; 2019; 17(5):324-334. PubMed ID: 31654514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efavirenz is associated with higher bone mass in South African children with HIV.
    Arpadi SM; Shiau S; Strehlau R; Patel F; Mbete N; McMahon DJ; Kaufman JJ; Coovadia A; Kuhn L; Yin MT
    AIDS; 2016 Oct; 30(16):2459-2467. PubMed ID: 27427876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching to Efavirenz Versus Remaining on Ritonavir-boosted Lopinavir in Human Immunodeficiency Virus-infected Children Exposed to Nevirapine: Long-term Outcomes of a Randomized Trial.
    Murnane PM; Strehlau R; Shiau S; Patel F; Mbete N; Hunt G; Abrams EJ; Coovadia A; Kuhn L
    Clin Infect Dis; 2017 Aug; 65(3):477-485. PubMed ID: 28419200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy.
    Arpadi S; Shiau S; Strehlau R; Martens L; Patel F; Coovadia A; Abrams EJ; Kuhn L
    Arch Dis Child; 2013 Apr; 98(4):258-64. PubMed ID: 23220209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia.
    Gleason RL; Caulk AW; Seifu D; Parker I; Vidakovic B; Getenet H; Assefa G; Amogne W
    PLoS One; 2015; 10(4):e0117125. PubMed ID: 25915208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment outcomes among HIV-1 and HIV-2 infected children initiating antiretroviral therapy in a concentrated low prevalence setting in West Africa.
    Okomo U; Togun T; Oko F; Peterson K; Townend J; Peterson I; Jaye A
    BMC Pediatr; 2012 Jul; 12():95. PubMed ID: 22770231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switch to Efavirenz Attenuates Lipoatrophy in Girls With Perinatal HIV.
    Su J; Shiau S; Arpadi SM; Strehlau R; Burke M; Patel F; Kuhn L; Coovadia A; Yin MT;
    J Pediatr Gastroenterol Nutr; 2021 Jan; 72(1):e15-e20. PubMed ID: 32804904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment.
    Shiau S; Kuhn L; Strehlau R; Martens L; McIlleron H; Meredith S; Wiesner L; Coovadia A; Abrams EJ; Arpadi SM
    BMC Pediatr; 2014 Feb; 14():39. PubMed ID: 24521425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
    Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
    BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased bone turnover in HIV-infected children on antiretroviral therapy.
    Shiau S; Yin MT; Strehlau R; Patel F; Mbete N; Kuhn L; Coovadia A; Arpadi SM
    Arch Osteoporos; 2018 Apr; 13(1):40. PubMed ID: 29623447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid profiles in young HIV-infected children initiating and changing antiretroviral therapy.
    Strehlau R; Coovadia A; Abrams EJ; Martens L; Arpadi S; Meyers T; Kuhn L
    J Acquir Immune Defic Syndr; 2012 Aug; 60(4):369-76. PubMed ID: 22134152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
    McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
    Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.
    De Luca A; Cozzi-Lepri A; Antinori A; Zaccarelli M; Bongiovanni M; Di Giambenedetto S; Marconi P; Cicconi P; Resta F; Grisorio B; Ciardi M; Cauda R; Monforte Ad; ; ; ;
    Antivir Ther; 2006; 11(5):609-18. PubMed ID: 16964829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.
    Dlamini JN; Hu Z; Somaroo H; Highbarger HC; Follmann DA; Dewar RL; Pau AK
    Pharmacotherapy; 2011 Feb; 31(2):158-63. PubMed ID: 21275494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical Trial.
    Coovadia A; Abrams EJ; Strehlau R; Shiau S; Pinillos F; Martens L; Patel F; Hunt G; Tsai WY; Kuhn L
    JAMA; 2015 Nov; 314(17):1808-17. PubMed ID: 26529159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efavirenz and ritonavir-boosted lopinavir use exhibited elevated markers of atherosclerosis across age groups in people living with HIV in Ethiopia.
    Gleason RL; Caulk AW; Seifu D; Rosebush JC; Shapiro AM; Schwartz MH; Eckard AR; Amogne W; Abebe W
    J Biomech; 2016 Sep; 49(13):2584-2592. PubMed ID: 27270208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART.
    Casado JL; de Los Santos I; Del Palacio M; García-Fraile L; Pérez-Elías MJ; Sanz J; Moreno S
    HIV Clin Trials; 2013; 14(1):1-9. PubMed ID: 23372109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3 trial.
    Musiime V; Cook A; Kayiwa J; Zangata D; Nansubuga C; Arach B; Kenny J; Wavamunno P; Komunyena J; Kabamba D; Asiimwe AR; Mirembe G; Abongomera G; Mulenga V; Kekitiinwa A; Kityo C; Walker SA; Klein N; Gibb DM;
    Antivir Ther; 2014; 19(3):269-76. PubMed ID: 24717427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth Recovery Among HIV-infected Children Randomized to Lopinavir/Ritonavir or NNRTI-based Antiretroviral Therapy.
    Achan J; Kakuru A; Ikilezi G; Mwangwa F; Plenty A; Charlebois E; Young S; Havlir D; Kamya M; Ruel T
    Pediatr Infect Dis J; 2016 Dec; 35(12):1329-1332. PubMed ID: 27580060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.